Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …

PURPOSE Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large
B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship …

Abstract PET using 18 F-FDG for treatment monitoring in patients with lymphoma is one of
the most well-developed clinical applications. PET/CT is nowadays used during treatment to …

Purpose Interim positron emission tomography (PET) using the tracer,[18F]
fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin …

Increased tumor burden is associated with inferior outcomes in many lymphoma subtypes.
Surrogates of tumor burden that are easy to measure, such as the maximum tumor …

Consolidative radiation therapy (RT) for advanced-stage diffuse large B-cell lymphoma
(DLBCL) remains controversial, with routine practice continuing to include RT in patients …

Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70%
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …

Abstract FDG‐PET/CT is the current state‐of‐the‐art imaging in lymphoma and plays a
central role in treatment decisions. At diagnosis, accurate staging is crucial for appropriate …